Histone deacetylase inhibitors: Keeping momentum for neuromuscular and cardiovascular diseases treatment

被引：39

作者：

Colussi, Claudia ^{[2
]}

Illi, Barbara ^{[2
]}

Rosati, Jessica ^{[1
]}

Spallotta, Francesco ^{[1
]}

Farsetti, Antonella ^{[3
]}

Grasselli, Annalisa ^{[3
,4
]}

Mai, Antonello ^{[5
]}

Capogrossi, Maurizio C. ^{[1
]}

Gaetano, Carlo ^{[1
]}

机构：

[1] Ist Dermopat Immacolata, Lab Patol Vasc, I-00167 Rome, Italy

[2] Ist Cardiol Monzino, Lab Biol Vasc & Med Rigenerat, Milan, Italy

[3] CNR, Ist Neurobiol & Med Mol, Rome, Italy

[4] Ist Nazl Ricovero & Cura Anziano, Ancona, Italy

[5] Univ Roma La Sapienza, Dipartimento Sci Chim, Rome, Italy

来源：

PHARMACOLOGICAL RESEARCH | 2010年 / 62卷 / 01期

关键词：

Neuromuscular disorders; HDAC; HDAC inhibitors; Cardiovascular diseases; CLASS-II; NITRIC-OXIDE; CARDIAC-HYPERTROPHY; MOUSE MODEL; SODIUM-BUTYRATE; HDAC INHIBITION; DYSTROPHY; EXPRESSION; MUSCLE; HEART;

D O I：

10.1016/j.phrs.2010.02.014

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Histone deacetylases (HDACs) are enzymes with a pleiotropic range of intracellular localizations and actions. They are principally involved in the withdrawal of acetyl-groups from a large number of nuclear and cytoplasmic proteins including nuclear core histones as well as cytoskeletal proteins and metabolically relevant enzymes. Initial findings indicated that HDAC inhibitors (DIs) could be successfully applied in a variety of cancer treatment protocols as a consequence of their anti-proliferative and pro-apoptotic properties. Recent observations, however, enlightened the important therapeutic effects of DIs in experimental animal models for arthritis, neurodegenerative and neuromuscular disorders, heart ischemia, cardiac hypertrophy, heart failure and arrhythmias. A small number of clinical trials are now open or planned for the near future to verify the therapeutic properties of DIs in non-cancer-related diseases. This review summarizes some of the most important observations and concepts aroused by the most recent experimental application of DIs to neuromuscular and cardiac diseases. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：3 / 10

页数：8

共 127 条

[61] Inhibitors of histone deacetylase as new anticancer agents [J].

Jung, M .

CURRENT MEDICINAL CHEMISTRY, 2001, 8 (12) :1505-1511

[62] Therapeutic application of histone deacetylase inhibitors for central nervous system disorders [J].

Kazantsev, Aleksey G. ;

Thompson, Leslie M. .

NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (10) :854-868

[63] Activation of Histone Deacetylase 2 by Inducible Heat Shock Protein 70 in Cardiac Hypertrophy [J].

Kee, Hae Jin ;

Eom, Gwang Hyeon ;

Joung, Hosouk ;

Shin, Sera ;

Kim, Ju-Ryoung ;

Cho, Young Kuk ;

Choe, Nakwon ;

Sim, Bo-Woong ;

Jo, Daewoong ;

Jeong, Myung Ho ;

Kim, Kyung Keun ;

Seo, Jeong-Sun ;

Kook, Hyun .

CIRCULATION RESEARCH, 2008, 103 (11) :1259-U120

[64] Drug Insight: histone deacetylase inhibitors - development of the new targeted anticancer agent suberoylanilide hydroxamic acid [J].

Kelly, WK ;

Marks, PA .

NATURE CLINICAL PRACTICE ONCOLOGY, 2005, 2 (03) :150-157

[65] Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors [J].

Khan, Nagma ;

Jeffers, Michael ;

Kumar, Sampath ;

Hackett, Craig ;

Boldog, Ferenc ;

Khramtsov, Nicholai ;

Qian, Xiaozhong ;

Mills, Evan ;

Berghs, Stanny C. ;

Carey, Nessa ;

Finn, Paul W. ;

Collins, Laura S. ;

Tumber, Anthony ;

Ritchie, James W. ;

Jensen, Peter Buhl ;

Lichenstein, Henri S. ;

Sehested, Maxwell .

BIOCHEMICAL JOURNAL, 2008, 409 :581-589

[66] Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes [J].

Kim, MS ;

Kwon, HJ ;

Lee, YM ;

Baek, JH ;

Jang, JE ;

Lee, SW ;

Moon, EJ ;

Kim, HS ;

Lee, SK ;

Chung, HY ;

Kim, CW ;

Kim, KW .

NATURE MEDICINE, 2001, 7 (04) :437-443

[67] Oxidative stress in asthma and COPD: Antioxidants as a therapeutic strategy [J].

Kirkham, Paul ;

Rahman, Irfan .

PHARMACOLOGY & THERAPEUTICS, 2006, 111 (02) :476-494

[68] Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy [J].

Kong, Yongli ;

Tannous, Paul ;

Lu, Guangrong ;

Berenji, Kambeez ;

Rothermel, Beverly A. ;

Olson, Eric N. ;

Hill, Joseph A. .

CIRCULATION, 2006, 113 (22) :2579-2588

[69] Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop [J].

Kook, H ;

Lepore, JJ ;

Gitler, AD ;

Lu, MM ;

Yung, WWM ;

Mackay, J ;

Zhou, R ;

Ferrari, V ;

Gruber, P ;

Epstein, JA .

JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (06) :863-871

[70] Functional differences in epigenetic modulators - Superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies [J].

Kozikowski, Alan P. ;

Chen, Yufeng ;

Gaysin, Arsen ;

Chen, Bin ;

D'Annibale, Melissa A. ;

Suto, Carla M. ;

Langley, Brett C. .

JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (13) :3054-3061

← 2 3 4 5 6 7 8 9 10 11 →